文献速递角膜与眼表疾病

S100A8/A9通过调控Acod1/STAT3通路促进干燥综合征干眼病中树突状细胞介导的Th17细胞反应

S100A8/A9 Promotes Dendritic Cell-Mediated Th17 Cell Response in Sjögren's Dry Eye Disease by Regulating the Acod1/STAT3 Pathway.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究探讨S100A8/A9在干燥综合征干眼病(SjDED)发病中的作用及机制。S100A8/A9在SjDED患者外周血单核细胞和SjDED小鼠泪腺中表达上调,且与干眼严重程度及泪腺炎症浸润水平相关。S100A8/A9抑制剂paquinimod可改善SjDED小鼠临床及组织病理学表型并减少Th17细胞比例,机制上S100A8/A9通过诱导Acod1表达促进STAT3活化和核转位,增加Il23a转录,从而增强树突状细胞驱动的Th17细胞反应。

要点

  • S100A8/A9在SjDED患者外周血单核细胞和SjDED小鼠泪腺中表达上调,且与干眼严重程度及泪腺炎症浸润水平相关。
  • S100A8/A9抑制剂paquinimod可改善SjDED小鼠临床及组织病理学表型,并减少泪腺、淋巴结和脾脏中Th17细胞比例。
  • S100A8/A9通过Acod1/STAT3通路促进树突状细胞MHCⅡ和Th17极化细胞因子表达,进而增强Th17细胞反应。

核心结论

  • S100A8/A9激活Acod1/STAT3通路促进SjDED中树突状细胞驱动的Th17细胞反应。
  • S100A8/A9/Acod1/STAT3通路可能成为SjDED有前景的治疗靶点。

研究设计与样本

  • 研究检测S100A8/A9在SjDED患者外周血单核细胞及SjDED小鼠泪腺中的表达。
  • 使用非肥胖糖尿病(NOD)小鼠评估S100A8/A9抑制剂paquinimod对干眼病的影响。
  • 通过免疫荧光和流式细胞术评估免疫细胞浸润及百分比。
  • 通过western blot、免疫荧光和染色质免疫沉淀分析作用机制。

主要发现

  • S100A8/A9在SjDED患者外周血单核细胞和SjDED小鼠泪腺中表达上调,且与干眼严重程度及泪腺炎症浸润水平相关。
  • 给予paquinimod改善SjDED小鼠临床及组织病理学表型,并减少泪腺、淋巴结和脾脏中Th17细胞比例。
  • S100A8/A9不直接影响Th17细胞生成和功能,而是上调树突状细胞中MHCⅡ和Th17极化细胞因子表达以增强Th17细胞反应。
  • S100A8/A9诱导Acod1表达,促进STAT3活化和核转位,导致Il23a转录增加。
  • STAT3激活剂逆转paquinimod对SjDED小鼠的治疗效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the role of S100A8/A9 in the pathogenesis of Sjögren's dry eye disease (SjDED) and explore its potential mechanism of action. METHODS: S100A8/A9 expression was determined by western blot and quantitative real-time polymerase chain reaction (qRT-PCR). Tear secretion, corneal fluorescein staining, and hematoxylin and eosin staining were used to evaluate the effect of paquinimod, a S100A8/A9 inhibitor, on dry eye disease in nonobese diabetic (NOD) mice. Immune cell infiltration and percentage were assessed by immunofluorescence and flow cytometry. Proinflammatory cytokine levels were examined by qRT-PCR or ELISA. The mechanism of action was analyzed using western blot, immunofluorescence, and chromatin immunoprecipitation. RESULTS: S100A8/A9 was upregulated in peripheral blood mononuclear cells of patients with SjDED and lacrimal glands (LGs) of SjDED mice. The upregulation of S100A8/A9 was correlated with the dry eye severity and inflammatory infiltration levels in LGs. Administration of paquinimod ameliorated clinical and histopathological phenotypes of SjDED mice and reduced the proportion of Th17 cells in LGs, lymph nodes, and spleens. Further experiments revealed that S100A8/A9 did not directly affect Th17 generation and function but upregulated the expression of major histocompatibility complex Ⅱ (MHC Ⅱ) and Th17-polarizing cytokines in dendritic cells (DCs) to augment Th17 cell response. Mechanistically, S100A8/A9 induced the expression of Acod1 and thereby promoted the activation and nuclear translocation of signal transducer and activator of transcription 3 (STAT3), resulting in increased Il23a transcription. STAT3 activator reversed the therapeutic effect of paquinimod on SjDED mice. CONCLUSIONS: S100A8/A9 activated the Acod1/STAT3 pathway to promote DC-driven Th17 cell responses in SjDED. The S100A8/A9/Acod1/STAT3 pathway may represent a promising therapeutic target for SjDED.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wei Y, Sun M, Zhang X, et al. S100A8/A9 Promotes Dendritic Cell-Mediated Th17 Cell Response in Sjögren's Dry Eye Disease by Regulating the Acod1/STAT3 Pathway. Invest Ophthalmol Vis Sci. 2025. PMID: 39808117. doi:10.1167/iovs.66.1.35

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。